BiomX Inc. (PHGE)
| Market Cap | 11.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.71M |
| Shares Out | 18.18M |
| EPS (ttm) | -3.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,757 |
| Open | 0.567 |
| Previous Close | 0.569 |
| Day's Range | 0.567 - 0.630 |
| 52-Week Range | 0.480 - 8.550 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 22.50 (+3,529.03%) |
| Earnings Date | Nov 14, 2024 |
About PHGE
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PHGE stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 3,529.03% from the latest price.
News
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conferenc...
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX Announces a Mandatory Unit Separation
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units...
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & C...
BiomX Inc. Announces 1-for-10 Reverse Stock Split
GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
Top 3 Health Care Stocks That May Explode In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...
BiomX (PHGE) Q1 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE) Q1 2024 Earnings Conference Call May 21, 2024 8:00 AM ET Company Participants Jonathan Solomon - Chief Executive Officer Avi Gabay - Chief Financial Officer Conference Call Par...
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engine...
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024 Abstract selected as a “Top Poster”, ranking it among the 1-...
BiomX Announces the Appointment of Susan Blum to its Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies ...
BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE) Q4 2023 Earnings Conference Call April 3, 2024 8:00 AM ET Company Participants Avi Gabay - Interim CFO Jonathan Solomon - CEO Conference Call Participants Joseph Pantginis - H....
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...